ER-100 and Partial Reprogramming in Humans: OSK Gene Therapy for the Visual System

1. Introduction: The First Human Partial-Reprogramming Trial

Partial reprogramming — the transient expression of reprogramming factors to reduce cellular age without erasing identity — restored vision in old and glaucomatous mice. ER-100, developed by Life Biosciences, is the attempt to translate that result into the first human reprogramming therapy. It is an AAV-delivered OSK (Oct4, Sox2, Klf4; c-Myc omitted) cassette injected into the eye for optic neuropathies, with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION) as the first indications. The eye is a deliberate beachhead: it is accessible, relatively immune-privileged, and its function can be measured precisely.

This article is careful about what the human trial does and does not represent. The Phase 1 study is primarily a safety and tolerability study in a small number of patients; its efficacy assessments are exploratory. The mouse and nonhuman-primate data are encouraging but do not guarantee that OSK reprogramming will benefit people. Claims that the trial constitutes a demonstration of rejuvenation in humans are premature: it is the first test of whether reprogramming is safe and does anything measurable, not a result.

2. The Science: OSK and Partial Reprogramming

2.1. From Yamanaka Factors to OSK

The four Yamanaka factors (OSKM) convert differentiated cells into pluripotent stem cells by rewriting their epigenetic program, but full reprogramming erases cell identity and creates proliferative and teratoma risk; c-Myc is itself oncogenic. The OSK combination drops c-Myc and is used only transiently, under an inducible promoter, so that expression is switched on for a defined window and then turned off. In the eye, this is achieved with a doxycycline-responsive (Tet-On) AAV system: the reprogramming factors are expressed while the patient takes doxycycline and stop when it is withdrawn.

2.2. Retinal Ganglion Cells and Optic Neuropathies

Retinal ganglion cells (RGCs) are the neurons that carry visual information from the retina to the brain; their axons form the optic nerve. RGCs do not regenerate, so their loss causes permanent vision loss. In NAION («stroke of the eye») blood flow to the optic nerve fails and vision is lost suddenly; in open-angle glaucoma, the optic nerve degenerates progressively, often in association with elevated intraocular pressure. Both increase in frequency with age, and existing treatments slow but do not reverse the underlying neuronal degeneration. A therapy that could protect or restore RGC function would address an unmet need regardless of its connection to «aging.»

2.3. The Mouse Evidence Base

The foundational result is Lu and colleagues (Nature, 2020): virally delivered OSK reversed epigenetic age in RGCs, restored youthful DNA-methylation and transcriptome patterns, promoted axon regeneration after optic-nerve crush injury, and restored visual acuity in aged and glaucomatous mice, without observed tumor formation. The mechanism appeared to depend on active DNA demethylation via Tet1/Tet2. Subsequent work (Karg et al., Cellular Reprogramming, 2023) extended this to a year-long study using a doxycycline-inducible dual-AAV system: roughly two months of induced OSK restored impaired vision to healthy levels, the benefit was sustained for many months, and continuous OSK expression over 21 months produced no detectable adverse effects on retinal structure in mice. This is strong, well-replicated evidence in mice. It is not evidence of efficacy or safety in humans.

3. What ER-100 Is

ER-100 is an AAV-based gene therapy administered as a single intravitreal injection into one eye. The vector carries the OSK transcription factors under a doxycycline-inducible control element; expression is activated by systemic doxycycline taken for eight weeks. It does not edit the patient’s genome, and the vector is engineered to be replication-incompetent. Life Biosciences describes the platform as «partial epigenetic reprogramming» — the intended effect is to reset gene-expression patterns in RGCs toward a more youthful, functional state, without changing DNA. The same OSK platform is being explored in a separate liver program (ER-300) for MASH.

4. The Clinical Program

At the Aging Research and Drug Discovery meeting in August 2025, Life Biosciences presented preclinical data from a nonhuman-primate model of NAION. ER-100 produced expression of all three factors in a fraction of cells in the ganglion-cell layer (reported at roughly 10-25%), restored NAION-induced DNA-methylation changes with enrichment of neuronal-regeneration signatures, improved pattern electroretinogram (pERG) amplitudes by a few microvolts, and mitigated structural damage. The treatment was reported as well tolerated, with only transient, procedure- and AAV-associated ocular inflammation that resolved. These are nonhuman-primate preclinical data, presented by the company; they are the bridge to the human study, not a human result.

The FDA cleared the Investigational New Drug application in January 2026 (the company announced the clearance on January 28, 2026). The Phase 1 study (NCT07290244) is a first-in-human, single-dose safety and tolerability trial. It has two sequential parts: a dose-escalation cohort in open-angle glaucoma and a dose-expansion cohort in NAION, for a planned total of up to 18 participants (approximately 12 with OAG and 6 with NAION). Participants receive a single injection into one eye, activated by eight weeks of doxycycline. The study began in March 2026, the first participant was dosed in June 2026, and primary completion is estimated for 2027. The company describes it as the first clinical trial of partial epigenetic reprogramming — a company claim that is accurate as a statement of priority but should not be read as a claim of efficacy.

5. What Has Actually Been Demonstrated

6. Risks and Limitations

• Proliferation and teratoma risk. Even Myc-free OSK reprogramming carries theoretical risk if expression is not tightly controlled; the doxycycline switch-off is a safety design, but the inducible system is itself an unproven control in humans.
• AAV immunogenicity and delivery. AAV vectors can provoke immune responses, and expression is limited to transduced cells; only a minority of target cells may be reached.
• Durability. In mice the benefit diminished after OSK was switched off; whether reprogrammed human RGCs retain function long term is unknown.
• Species translation. A nonhuman-primate NAION model is a stronger bridge than mice, but primate methylation and functional results still do not establish human benefit.
• Small, safety-focused design. A Phase 1 study of up to 18 patients cannot establish efficacy; any visual improvement will be hypothesis-generating and require controlled confirmation.
• Single-eye treatment. ER-100 is injected into one eye; a within-patient comparison of treated versus untreated eye is informative but not equivalent to a placebo-controlled design.

7. Prospects

Restoring sight to people who have lost it would be a meaningful healthspan gain on its own terms — vision loss is associated with falls, isolation, cognitive decline, and mortality. More strategically, ER-100 is a scout for the entire reprogramming field: if controlled OSK expression can be shown to be safe and to improve function in one human tissue, the platform logic becomes more credible for other organs. But the trial’s first obligation is to rule out harm, and the readouts that matter most are long-term safety and durability. Any claim that ER-100 «reverses aging» in humans ahead of those results is speculative.

Sources and Key Research Centers

1. Lu Y, Brommer B, Tian X, et al. «Reprogramming to recover youthful epigenetic information and restore vision.» Nature, 2020; 588(7836): 124-129. DOI: 10.1038/s41586-020-2975-4
2. Karg MM, Lu YR, Refaian N, et al. «Sustained vision recovery by OSK gene therapy in a mouse model of glaucoma.» Cellular Reprogramming, 2023; 25(6): 288-299. DOI: 10.1089/cell.2023.0074
3. Ocampo A et al. «In vivo amelioration of age-associated phenotypes by partial reprogramming.» Cell, 2016; 167(7): 1719-1733.e12. DOI: 10.1016/j.cell.2016.11.052
4. Life Biosciences — developer of ER-100; Partial Epigenetic Reprogramming platform, ARDD 2025 preclinical data (nonhuman-primate NAION), and the January 2026 FDA IND clearance announcement.
5. ClinicalTrials.gov NCT07290244 — Phase 1 study of ER-100 in OAG and NAION: design, dosing, and recruitment status.
6. Harvard Medical School / Schepens Eye Research Institute — retinal ganglion cell biology and OSK reprogramming research (Sinclair, Ksander, Gregory-Ksander).